uMotif

uMotif is a UK-based clinical trial management platform that was designed to simplify the clinical trial process for patients. The platform can be used to manage multiple phases including 1) patient onboarding and screening, 2) electronic clinical outcome assessments, 3) electronic patient-reported outcomes, 4) electronic consent, and 5) connectivity with medical IoT devices.

The company’s platform is compliant with industry standards including GCP, 21 CFR Part 11, GDPR, and HIPAA

In September 2024, the company acquired ClinOne, a company that offers site applications including eConsent, for an undisclosed sum. ClinOne provided an integrated platform that connects, informs, and empowers clinical trial sites. Its offerings included consent management, site productivity tools, trial awareness enhancement, and patient and caregiver experience improvements, all supported by data insight tools and standards-based interoperability. At the time of the acquisition, ClinOne reported that it had 2,000+ sponsor and CRO customers, supported 7,200+ trial sites, facilitated 4,500+ studies, and was available in 60+ languages to date.

Geographically, the company notes that, as of June 2024, it operated across 30+ countries.

Key customers and partnerships

As of May 2022, uMotif’s customer base included established pharmaceutical players such as Novartis, AstraZeneca, Merck, and SyneosHealth.

In terms of partnerships, the company was working with organizations from technology infrastructure partners, such as Amazon Web Services, to pharmaceutical players, such as AbbVie for “Bring Your Own Device” application support. It also works with academic institutions such as the University of Manchester for application support.

In March 2023, the company partnered with advanced biostatistics consultancy firm Veramed to offer advanced biostatical data analysis and eCOA/ePRO data capture. Through the partnership, sponsors using uMotif’s platform were able to use Veramed’s data analysis tools and visualization support on top of uMotif’s platform for ePRO/eCOA data capture, reporting, and analytics.

In February 2024, the company partnered with MoCA Cognition, a developer of a test for early cognitive impairment detection, to make it easier for sponsors and CROs to capture quality cognitive function and eCOA/ePRO data for CNS research. Through the partnership, MoCA’s test results could be uploaded into the uMotif platform for central rating and review.

Funding and financials

The company raised GBP 5 million in Series A funding in September 2020, primarily to speed up product development and go-to-market activity.